What is the level of liabilities of Formycon this year?
Formycon has a debt balance of 387.61 M EUR this year.
Formycon Liabilities 2024
Formycon Liabilities
387.61 M EUR
Ticker
FYB.DE
ISIN
DE000A1EWVY8
WKN
A1EWVY
In 2024, Formycon's total liabilities amounted to 387.61 M EUR, a -22.03% difference from the 497.12 M EUR total liabilities in the previous year.
Formycon Aktienanalyse
What does Formycon do?
Formycon AG is a German biotechnology company that was founded in 2010 in Martinsried near Munich. The company's history mainly began with the development of an innovative technology concept that allows for the cost-effective and efficient production of biosimilars. The market entry started in 2017 with the launch of the first proprietary biosimilar on the European market. The core business of Formycon AG is the production and distribution of biosimilars. These are biological drugs that have a similar structure and efficacy to already approved original drugs. The development of biosimilars is complex due to the elaborate manufacturing process and high-quality assurance requirements, requiring innovative ideas and technologies. Formycon AG has developed its innovative platform technology, FORMYCON® NEXT LEVEL, which allows the company to cost-effectively produce large quantities of proteins used in cancer therapy, immunotherapy, and the treatment of autoimmune diseases. Formycon AG is divided into various divisions, including research and development, production, and distribution. In research and development, new biosimilars and other innovative technologies are developed to further improve production processes. Production takes place in a dedicated biotechnological production facility in Roth near Nuremberg, where up to eight different medications can be produced simultaneously. In the distribution sector, Formycon AG collaborates with partners who market and distribute the biosimilars in different countries. The company operates internationally, with a presence in Europe, the USA, and Asia. The biosimilars produced by Formycon AG are a cost-effective alternative to the existing original drugs. The products are used in the fields of oncology, immunology, and ophthalmology, offering patients a chance to receive effective therapy at an affordable price. Successful marketing and high demand contribute to positive company development. In 2020, Formycon AG generated a revenue of 25 million euros and currently employs approximately 150 staff members. An example of a biosimilar produced by Formycon AG is the drug FYB202, which is used for the treatment of breast, ovarian, and salivary gland cancer. It is a replica of the breast cancer medication Herceptin®, developed and distributed by the Swiss company Roche. The FYB202 biosimilar has shown in clinical studies that it is similarly effective as Herceptin® but represents a more cost-effective alternative for patients. Overall, Formycon AG pursues a sustainable business model with a focus on the development of cost-effective biosimilars. The innovative technology and focus on cost-effective production enable the company to achieve a strong market presence and offer an effective alternative to conventional drugs. Formycon ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Formycon's Liabilities
Formycon's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Formycon's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Formycon's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Formycon's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Formycon’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Formycon stock
What were the liabilities of Formycon compared to the previous year?
The liabilities of Formycon have increased by -22.03% dropped compared to the previous year.
What are the consequences of high debt for investors of Formycon?
High liabilities can pose a risk for investors of Formycon, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Formycon?
Low liabilities mean that Formycon has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Formycon affect the company?
An increase in liabilities of Formycon can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Formycon affect the company?
A decrease in the liabilities of Formycon can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Formycon?
Some factors that can influence the liabilities of Formycon include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Formycon so important for investors?
The liabilities of Formycon are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Formycon take to modify the liabilities?
To change its liabilities, Formycon can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Formycon pay?
Over the past 12 months, Formycon paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Formycon is expected to pay a dividend of 0 EUR.
What is the dividend yield of Formycon?
The current dividend yield of Formycon is .
When does Formycon pay dividends?
Formycon pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Formycon?
Formycon paid dividends every year for the past 0 years.
What is the dividend of Formycon?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Formycon located?
Formycon is assigned to the 'Health' sector.
Wann musste ich die Aktien von Formycon kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Formycon from 11/14/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 11/14/2024.
When did Formycon pay the last dividend?
The last dividend was paid out on 11/14/2024.
What was the dividend of Formycon in the year 2023?
In the year 2023, Formycon distributed 0 EUR as dividends.
In which currency does Formycon pay out the dividend?
The dividends of Formycon are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Formycon stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Formycon
Our stock analysis for Formycon Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Formycon Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
